Elijah E. Cummings Family Asthma Act
Summary
HR6052, the Elijah E. Cummings Family Asthma Act, is an early-stage bill that amends the Public Health Service Act to direct further asthma research. It authorizes no specific funding, mandates no changes to healthcare providers or pharmaceutical companies, and has been referred to committee with four cosponsors. No near-term market impact is expected.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR6052 is a zero-funding, procedural bill that does not allocate money or mandate any healthcare changes
- 2.No public company's revenue or competitive position is affected by this legislation
- 3.Investors should not make portfolio decisions based on this bill in its current form
Market Implications
No market implications. This bill has no mechanism to affect company revenues, costs, or competitive dynamics. Asthma-related pharmaceutical and device companies are not impacted, as the bill merely directs research without funding or regulatory changes. No ticker action is warranted.
Full Analysis
-
What happened: On November 17, 2025, Rep. Debbie Dingell (D-MI) introduced HR6052 in the House. The bill was referred to the Energy and Commerce Committee and has not advanced further. It has four cosponsors, all in the House, and remains in early legislative stage.
-
The money trail: The bill amends the Public Health Service Act to direct research activities but authorizes zero specific funding. Authorization without appropriation means no actual money is allocated. For market impact, a separate appropriations bill would be needed, which has not been introduced. The total addressable market for asthma treatments ($81.9B annual cost cited in findings) is unaffected by this procedural bill.
-
Structural winners and losers: This bill's passage would not change current law regarding asthma research funding, treatment guidelines, or insurance coverage. No public company's revenue stream is directly affected. Asthma-related tickers (e.g., $TEVA, $GSK, $AZN for inhalers; $REGN for biologics) are not impacted because the bill does not mandate coverage changes, pricing reforms, or new subsidies.
-
Competitive landscape: No real market data provided. The asthma treatment market continues to be driven by FDA approvals, patent expirations, and insurance coverage policies—none of which this bill addresses.
-
Timeline: The bill must pass committee, then the full House, then the Senate (or have a companion bill introduced), then be signed into law. With no companion bill and only four cosponsors, passage in the 119th Congress is uncertain. Even if passed, market impact would be zero without an appropriations bill.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Protecting Americans from Unsafe Drugs Act of 2026
Biological Intellectual Property Protection Act of 2025
To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes.
To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.
Skinny Labels, Big Savings Act
Biosimilar Red Tape Elimination Act
Maternal Vaccination Act
Skinny Labels, Big Savings Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →